Amgen Impairment Charges decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$129.00M to $0.00. This is a positive signal — lower values indicate better performance for this metric.
High impairment charges suggest poor capital allocation or a decline in the competitive value of the company's assets.
Impairment charges are non-cash write-downs taken when the carrying value of an asset exceeds its fair market value. Thi...
Common in industries with high intangible asset bases, such as pharma and consumer goods.
cf_impairment_charges| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $141.75M | $141.75M | $141.75M | $141.75M | $0.00 | $0.00 | $0.00 | $0.00 | $68.00M | $0.00 | $61.00M | -$129.00M | $800.00M | $0.00 | $400.00M | $0.00 |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | -100.0% | — | -311.5% | +720.2% | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | >999% | — | +555.7% | +100.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.